Real-world effectiveness of third- or later-line treatment in Japanese patients with HER2-positive, unresectable, recurrent or metastatic gastric cancer: a retrospective observational study

BACKGROUND: Real-world evidence on the preference for and effectiveness of third- or later-line (3L +) monotherapy for HER2-positive gastric cancer is limited in Japan. This study evaluated the utility of nivolumab, irinotecan, and trifluridine/tipiracil (FTD/TPI) monotherapy as 3L + treatment in Ja...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakai, Daisuke, Omori, Takeshi, Fumita, Soichi, Fujita, Junya, Kawabata, Ryohei, Matsuyama, Jin, Yasui, Hisateru, Hirao, Motohiro, Kawase, Tomono, Kishi, Kentaro, Taniguchi, Yoshiki, Miyazaki, Yasuhiro, Kawada, Junji, Satake, Hironaga, Miura, Tomoko, Miyake, Akimitsu, Kurokawa, Yukinori, Yamasaki, Makoto, Yamada, Tomomi, Satoh, Taroh, Eguchi, Hidetoshi, Doki, Yuichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209345/
https://www.ncbi.nlm.nih.gov/pubmed/35489010
http://dx.doi.org/10.1007/s10147-022-02162-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209345/
https://www.ncbi.nlm.nih.gov/pubmed/35489010
http://dx.doi.org/10.1007/s10147-022-02162-4

Ejemplares similares